image: Human Longevity to sponsor ARDD 2025, the world's largest conference on aging research in the biopharmaceutical industry
Credit: ARDD
The University of Copenhagen is excited to announce Human Longevity, Inc. as Tier 1 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
Human Longevity, Inc. (HLI) is a leading longevity company at the forefront of delivering precision medicine, leveraging AI-powered diagnostics, whole genome sequencing, and multi-omics analysis to revolutionize early disease detection and longevity-focused care. Through its Executive Health and 100+ Longevity Programs, HLI delivers personalized, data-driven care for clients seeking to extend both lifespan and healthspan.
At ARDD 2025, HLI will share new insights from its longevity focused clinical programs on the real-world application of genomic and multi imaging-based risk detection, and longitudinal health data analytics for cancer prevention. As a Tier 1 Sponsor, HLI’s clinical and scientific leadership will participate in key sessions throughout the conference
“We are honored to support ARDD 2025 and align with the global leaders shaping the future of aging science,” said Wei-Wu He, Ph.D., Executive Chairman of Human Longevity. “By combining genomic data, advanced imaging, and AI, we are shifting the model from reactive care to proactive prevention.”
HLI’s translational focus is reflected in initiatives such as its $1 Million Cancer Prevention Pledge, which reinforces the company’s commitment to early detection and real-world clinical outcomes.
Through its partnership with ARDD, Human Longevity is proud to stand alongside Nobel laureates, pharmaceutical leaders, and fellow innovators in accelerating the translation of aging science into actionable, life-extending care.
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.